脂联素及其分泌调节

被引:22
作者
王淑芳催莹赵家军 [2 ]
机构
[1] 山东大学临床医学院济南市中心医院
[2] 山东省立医院 山东省济南市
关键词
医学生物化学; 脂联素; 综述; 脂肪细胞因子; 胰岛素抵抗;
D O I
暂无
中图分类号
R589 [代谢病];
学科分类号
1002 ; 100201 ;
摘要
脂联素是脂肪细胞特异性细胞因子,其血浆水平与胰岛素抵抗、肥胖症、2型糖尿病以及动脉硬化疾病的发病有关。目前已克隆到脂联素受体,过氧化物酶增殖物激活型受体γ配体和肿瘤坏死因子等细胞因子以及β肾上腺素能受体激动剂等因素均可参与脂联素的表达和分泌。对脂联素的进一步研究可为代谢性疾病的防治提供一条新的思路。
引用
收藏
页码:242 / 244
页数:3
相关论文
共 21 条
[1]  
Expression of adiponectin receptor in human macrophages andregulation by agonists of the nuclear receptor PPARalpha, PPARgamma, and LXR. Chinetti G,Zamadski C,Fruchart JC,Zawadski C,Fruchart JC,Steels B. Biochemical and Biophysical Research Communications . 2004
[2]  
Diabetes[P]. 英国专利:GB201117172D0,2011-11-16
[3]  
Reciprocal association of c-reactive protein with adiponectin in blood stream and adipose tissue. Ouchi N,Kihara S,Funahashi T,Nakamura T,Nishida M,Kumada M,et al. Circulation . 2003
[4]  
Growth hormone is apositive regulator of adiponectin receptor 2 in 3T3-L1 adipocytes. Fasshauer M,Klein J,Kralisch S,Klier M,Lossner U,Bluher M,et al. FEBS Letters . 2004
[5]  
Obesity,adiponectin and vascular inflammatory disease. Ouchi N,Kihara S,Funahashi T,Matsuzawa Y,Walsh K. Current Opinion in Lipidology . 2003
[6]  
Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Yamauchi T,Kamon T,Minokoshi Y,Ito Y,Waki H,Uchidu S,et al. Nature Medicine . 2002
[7]  
Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Yamanchi T,Kamon J,Ito Y,Tsuchida A,Yokomizo T,Kita S,et al. Nature . 2003
[8]  
Acrp30/adiponectin: an adipocytokine regulating glucose and lipid metabolism. Berg AH,Combs TP,Scherer PE. Trends in Endocrinology and Metabolism . 2002
[9]  
Adiponectin stimulates angiogenesis by promoting cross-talk between AMP-activated protein kinase and Akt signaling in endothelial cells. Ouchi N,Kobayashi H,Kihara S,Kumada M,Sato K,Inoue T,et al. Journal of Biological Chemistry . 2004
[10]  
Adiponectin represents an independent cardiovascular risk factor predicting serum HDL-cholesterol levels in type 2 diabetes. Zietz B,Herfarth H,Panl G,Paul G,Ehling A,Muller-Ladner U,et al. FBES Lett . 2003